C
Cheng Fu
Researcher at China Medical University (PRC)
Publications - 6
Citations - 147
Cheng Fu is an academic researcher from China Medical University (PRC). The author has contributed to research in topics: Sunitinib & Sorafenib. The author has an hindex of 4, co-authored 6 publications receiving 60 citations.
Papers
More filters
Journal ArticleDOI
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Ai Ping Zhou,Yuxian Bai,Yan Song,Hong Luo,Xiu Bao Ren,Xiuwen Wang,Benkang Shi,Cheng Fu,Ying Cheng,Ji-Yan Liu,Shukui Qin,Jun Li,Hanzhong Li,Xianzhong Bai,Dingwei Ye,Jinwan Wang,Jianhui Ma +16 more
TL;DR: The clinical efficacy of anlotinib was similar to that of sunitinib as the first-line treatment for mRCC, but with a more favorable safety profile.
Journal ArticleDOI
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
Dingwei Ye,Ji-Yan Liu,Aiping Zhou,Qing Zou,Hanzhong Li,Cheng Fu,Hailong Hu,Jian Huang,Shaoxing Zhu,Jie Jin,Lulin Ma,Jianming Guo,Jun Xiao,Se Hoon Park,Dahong Zhang,Xiusong Qiu,Yuanyuan Bao,Lilin Zhang,Wei Shen,F. Bi +19 more
TL;DR: Tislelizumab demonstrated meaningful clinical benefits in patients with previously treated locally advanced or metastatic PD‐L1‐positive urothelial carcinoma and had a manageable safety profile.
Journal ArticleDOI
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Jianhui Ma,Yan Song,Jianzhong Shou,Yuxian Bai,Hanzhong Li,Xiaodong Xie,Hong Luo,Xiubao Ren,Ji-Yan Liu,Dingwei Ye,Xianzhong Bai,Cheng Fu,Shukui Qin,Jinwan Wang,Aiping Zhou +14 more
TL;DR: Anlotinib showed promising efficacy as well as favorable safety as second-line treatment for patients with mRCC as assessed in a single-arm, open-label, phase 2 study.
Journal ArticleDOI
Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.
Aiping Zhou,Yuxian Bai,Yan Song,Hangzhong Li,Xiaodong Xie,Xiubao Ren,Dingwei Ye,Ji-Yan Liu,Hong Luo,Xianzhong Bai,Shukui Qin,Cheng Fu,Jinwan Wang,Jianhui Ma +13 more
TL;DR: FGF signaling regulates tumor growth and vascularization and partly mediates antiangiogenic escape from VEGFR inhibitors and Sequential TKI treatment has shown encouraging results in FGF-naïve mice.
Journal ArticleDOI
Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.
Aiping Zhou,Jianhui Ma,Yuxian Bai,Yan Song,Hangzhong Li,Xiaodong Xie,Xiubao Ren,Dingwei Ye,Ji-Yan Liu,Hong Luo,Xianzhong Bai,Shukui Qin,Cheng Fu,Jinwan Wang +13 more
TL;DR: Anlotinib is a potent oral, small molecular TKI with a favorable safety profile in phase I clinical trial which mainly targets VEGFR1/2/3, FGFR2.